Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
It is suggested that Peroxiredoxin 6 (Prx-6) may provide cytoprotection and wound healing in YAMC cells. Ulcerative colitis (UC) patients were treated using granulocytapheresis (GCAP). After the treatment, Prx6 in the patients, which observed the therapeutic effect, increased. These results show that Prx-6 may be involved in mechanisms of inflammatory bowel disease (IBD) and be used as a marker of examination the therapeutic effect of IBD.
|